$verv 2023 Q4 10-K

Concept	2023 Q4	2023	2021
Revenue	$5.144M	$11.76M	$0.00
YoY Change	408.3%	505.77%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.28M	$49.94M	$18.87M
YoY Change	7.37%	33.05%	258.92%
% of Gross Profit
Research & Development	$46.81M	$184.9M	$68.20M
YoY Change	25.55%	42.16%	92.82%
% of Gross Profit
Depreciation & Amortization	$1.517M	$5.455M	$1.500M
YoY Change	64.0%	94.54%	15.38%
% of Gross Profit
Operating Expenses	$59.09M	$234.9M	$87.07M
YoY Change	21.28%	40.12%	114.31%
Operating Profit		-$223.1M	-$87.07M
YoY Change		34.67%	114.31%
Interest Expense	$6.341M	$23.17M	$142.0K
YoY Change	40.88%	237.35%	-12.35%
% of Operating Profit
Other Income/Expense, Net	-$713.0K	$23.33M	-$33.25M
YoY Change	-132.75%	179.31%	554.86%
Pretax Income	-$48.32M	-$199.8M	$120.3M
YoY Change	17.76%	26.99%	163.24%
Income Tax	$32.00K	$275.0K	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$48.35M	-$200.1M	-$120.3M
YoY Change	17.69%	27.12%	163.24%
Net Earnings / Revenue	-939.97%	-1701.55%
Basic Earnings Per Share		-$3.12	-$4.48
Diluted Earnings Per Share	-$0.69	-$3.12	-$4.477M
COMMON SHARES
Basic Shares Outstanding	63.75M	64.18M	26.87M
Diluted Shares Outstanding		64.18M	26.87M

Concept	2023 Q4	2023	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$624.0M	$624.0M	$360.4M
YoY Change	12.46%	12.46%	399.84%
Cash & Equivalents	$206.2M	$206.2M	$64.33M
Short-Term Investments	$417.8M	$417.8M	$296.1M
Other Short-Term Assets	$8.102M	$8.102M	$6.686M
YoY Change	10.4%	10.4%	260.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$637.9M	$637.9M	$367.1M
YoY Change	13.28%	13.28%	396.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$22.51M	$107.8M	$9.063M
YoY Change	19.85%	-2.58%	127.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.165M	$6.939M	$7.933M
YoY Change	270.09%	28.29%	1613.39%
Total Long-Term Assets	$114.7M	$114.7M	$17.00M
YoY Change	-1.14%	-1.14%	282.19%
TOTAL ASSETS
Total Short-Term Assets	$637.9M	$637.9M	$367.1M
Total Long-Term Assets	$114.7M	$114.7M	$17.00M
Total Assets	$752.7M	$752.7M	$384.1M
YoY Change	10.82%	10.82%	389.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.636M	$6.636M	$7.077M
YoY Change	173.76%	173.76%	19558.33%
Accrued Expenses	$20.18M	$30.37M	$14.95M
YoY Change	-2.84%	-7.04%	107.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$37.01M	$37.01M	$22.02M
YoY Change	5.45%	5.45%	201.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$189.0K	$116.2M	$4.748M
YoY Change	-33.22%	24.66%	-51.78%
Total Long-Term Liabilities	$189.0K	$116.2M	$4.748M
YoY Change	-33.22%	24.66%	-51.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$37.01M	$37.01M	$22.02M
Total Long-Term Liabilities	$189.0K	$116.2M	$4.748M
Total Liabilities	$153.2M	$153.2M	$26.77M
YoY Change	19.41%	19.41%	56.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$544.3M
YoY Change	58.12%
Common Stock	$1.144B
YoY Change	27.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$599.5M	$599.5M	$357.4M
YoY Change
Total Liabilities & Shareholders Equity	$752.7M	$752.7M	$384.1M
YoY Change	10.82%	10.82%	389.87%

Concept	2023 Q4	2023	2021
OPERATING ACTIVITIES
Net Income	-$48.35M	-$200.1M	-$120.3M
YoY Change	17.69%	27.12%	163.24%
Depreciation, Depletion And Amortization	$1.517M	$5.455M	$1.500M
YoY Change	64.0%	94.54%	15.38%
Cash From Operating Activities	-$40.68M	-$149.5M	-$77.88M
YoY Change	23.68%	22.25%	120.84%
INVESTING ACTIVITIES
Capital Expenditures	$2.185M	$9.283M	$4.359M
YoY Change	-56.02%	-29.84%	27.31%
Acquisitions
YoY Change
Other Investing Activities	-$6.708M	$36.97M	-$234.7M
YoY Change	-95.89%	-125.91%	392.08%
Cash From Investing Activities	-$8.893M	$27.69M	-$239.1M
YoY Change	-94.72%	-117.76%	367.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$31.71M
YoY Change		-20.7%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	177.4M	212.6M	377.1M
YoY Change	347.96%	-35.38%	307.1%
NET CHANGE
Cash From Operating Activities	-40.68M	-149.5M	-77.88M
Cash From Investing Activities	-8.893M	27.69M	-239.1M
Cash From Financing Activities	177.4M	212.6M	377.1M
Net Change In Cash	127.8M	90.72M	60.11M
YoY Change	-179.09%	79.04%	864.09%
FREE CASH FLOW
Cash From Operating Activities	-$40.68M	-$149.5M	-$77.88M
Capital Expenditures	$2.185M	$9.283M	$4.359M
Free Cash Flow	-$42.87M	-$158.8M	-$82.24M
YoY Change	13.22%	17.16%	112.56%

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001840574
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40489
CY2023	dei	Entity Registrant Name EntityRegistrantName	VERVE THERAPEUTICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-4800132
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	201 Brookline Avenue, Suite 601
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02215
CY2023	dei	City Area Code CityAreaCode	617
CY2023	dei	Local Phone Number LocalPhoneNumber	603-0070
CY2023	dei	Security12b Title Security12bTitle	Common stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	VERV
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	939900000
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	83619279
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	206180000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	115412000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	417770000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	439396000
CY2023Q4	verv	Collaboration Receivable CollaborationReceivable	5897000
CY2022Q4	verv	Collaboration Receivable CollaborationReceivable	1012000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8102000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7339000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	637949000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	563159000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22505000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18778000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4774000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4824000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	85295000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	91877000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2165000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	585000
CY2023Q4	us-gaap	Assets Assets	752688000
CY2022Q4	us-gaap	Assets Assets	679223000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6636000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2424000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20178000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20767000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10192000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11904000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	37006000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	35095000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	64715000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	70014000
CY2023Q4	verv	Success Payment Liability SuccessPaymentLiability	2720000
CY2022Q4	verv	Success Payment Liability SuccessPaymentLiability	2885000
CY2023Q4	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	48556000
CY2022Q4	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	20014000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	189000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	283000
CY2023Q4	us-gaap	Liabilities Liabilities	153186000
CY2022Q4	us-gaap	Liabilities Liabilities	128291000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81969693
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81969693
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61730816
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61730816
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	82000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	62000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1143453000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	895801000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	272000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-694000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-544305000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-344237000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	599502000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	550932000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	752688000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	679223000
CY2023	verv	Collaborations Revenue CollaborationsRevenue	11758000
CY2022	verv	Collaborations Revenue CollaborationsRevenue	1941000
CY2021	verv	Collaborations Revenue CollaborationsRevenue	0
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	184946000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	130095000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	68202000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	49936000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37533000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18865000
CY2023	us-gaap	Operating Expenses OperatingExpenses	234882000
CY2022	us-gaap	Operating Expenses OperatingExpenses	167628000
CY2021	us-gaap	Operating Expenses OperatingExpenses	87067000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-223124000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-165687000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-87067000
CY2023	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	0
CY2022	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	0
CY2021	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	25574000
CY2023	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	-165000
CY2022	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	-1486000
CY2021	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	7815000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23166000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6867000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	142000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	23331000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8353000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81969693
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61730816
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61730816
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	82000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	62000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1143453000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	895801000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	272000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-694000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	679223000
CY2023	verv	Collaborations Revenue CollaborationsRevenue	11758000
CY2021	verv	Collaborations Revenue CollaborationsRevenue	0
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	184946000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	130095000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	68202000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18865000
CY2023	us-gaap	Operating Expenses OperatingExpenses	234882000
CY2022	us-gaap	Operating Expenses OperatingExpenses	167628000
CY2021	us-gaap	Operating Expenses OperatingExpenses	87067000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-223124000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-165687000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-87067000
CY2023	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	0
CY2022	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	0
CY2021	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	25574000
CY2023	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	-165000
CY2022	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	-1486000
CY2021	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	7815000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23166000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6867000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	142000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	23331000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8353000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-33247000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-199793000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-157334000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-120314000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	275000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-200068000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157387000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-120314000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.12
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.12
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.91
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-33247000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-199793000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-157334000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-120314000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	275000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-200068000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157387000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-120314000
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.12
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.91
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.48
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.48
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64175137
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64175137
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54023653
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54023653
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26872036
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26872036
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-200068000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157387000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-120314000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	966000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-466000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-199102000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-157853000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-120550000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-63909000
CY2021	verv	Issuance Costs Of Series B Convertible Preferred Stock IssuanceCostsOfSeriesBConvertiblePreferredStock	241000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	218919000
CY2021	verv	Issuance Costs Of Common Stock From Initial Public Offering IssuanceCostsOfCommonStockFromInitialPublicOffering	25098000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	281584000
CY2021	verv	Stock Issued During Period Value Licensor Institutions StockIssuedDuringPeriodValueLicensorInstitutions	32490000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	966000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	780000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-236000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7072000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-120314000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	357352000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2175000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1069000
CY2022	verv	Stock Issued During Period Value Licensor Institutions StockIssuedDuringPeriodValueLicensorInstitutions	39986000
CY2022	verv	Issuance Costs Of Common Stock From Initial Public Offering IssuanceCostsOfCommonStockFromInitialPublicOffering	15924000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	242826000
CY2022	verv	Issuance Of Common Stock From At The Market Offering IssuanceOfCommonStockFromAtTheMarketOffering	1722000000
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.91
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.48
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.48
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64175137
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64175137
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54023653
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54023653
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26872036
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26872036
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-200068000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157387000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-120314000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	966000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-466000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-236000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-199102000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-157853000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-120550000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-63909000
CY2021	verv	Issuance Costs Of Series B Convertible Preferred Stock IssuanceCostsOfSeriesBConvertiblePreferredStock	241000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	218919000
CY2021	verv	Issuance Costs Of Common Stock From Initial Public Offering IssuanceCostsOfCommonStockFromInitialPublicOffering	25098000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	281584000
CY2021	verv	Stock Issued During Period Value Licensor Institutions StockIssuedDuringPeriodValueLicensorInstitutions	32490000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	966000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	780000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-236000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7072000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-120314000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	357352000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2175000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1069000
CY2022	verv	Stock Issued During Period Value Licensor Institutions StockIssuedDuringPeriodValueLicensorInstitutions	39986000
CY2022	verv	Issuance Costs Of Common Stock From Initial Public Offering IssuanceCostsOfCommonStockFromInitialPublicOffering	15924000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	242826000
CY2022	verv	Issuance Of Common Stock From At The Market Offering IssuanceOfCommonStockFromAtTheMarketOffering	1722000000
CY2022	verv	Issuance Of Common Stock From At The Market Offering Net Of Issuance Costs IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts	42900000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-466000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22477000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157387000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	550932000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1200000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1379000
CY2023	verv	Issuance Of Common Stock In Connection With The Lilly Agreement IssuanceOfCommonStockInConnectionWithTheLillyAgreement	54671000
CY2023	verv	Issuance Of Common Stock From At The Market Offering IssuanceOfCommonStockFromAtTheMarketOffering	728000000
CY2023	verv	Issuance Of Common Stock From At The Market Offering Net Of Issuance Costs IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts	20570000
CY2022	verv	Issuance Of Common Stock From At The Market Offering Net Of Issuance Costs IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts	42900000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-466000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22477000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157387000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	550932000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1200000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1379000
CY2023	verv	Issuance Of Common Stock In Connection With The Lilly Agreement IssuanceOfCommonStockInConnectionWithTheLillyAgreement	54671000
CY2023	verv	Issuance Of Common Stock From At The Market Offering IssuanceOfCommonStockFromAtTheMarketOffering	728000000
CY2023	verv	Issuance Of Common Stock From At The Market Offering Net Of Issuance Costs IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts	20570000
CY2023	verv	Issuance Costs Of Common Stock From Initial Public Offering IssuanceCostsOfCommonStockFromInitialPublicOffering	9013000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	134736000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	966000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35116000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-200068000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	599502000
CY2023	us-gaap	Profit Loss ProfitLoss	-200068000
CY2022	us-gaap	Profit Loss ProfitLoss	-157387000
CY2021	us-gaap	Profit Loss ProfitLoss	-120314000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5455000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2804000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1535000
CY2023	us-gaap	Net Investment In Lease Credit Loss Expense Reversal NetInvestmentInLeaseCreditLossExpenseReversal	6792000
CY2022	us-gaap	Net Investment In Lease Credit Loss Expense Reversal NetInvestmentInLeaseCreditLossExpenseReversal	3907000
CY2021	us-gaap	Net Investment In Lease Credit Loss Expense Reversal NetInvestmentInLeaseCreditLossExpenseReversal	1842000
CY2023	verv	Net Amortization Of Premium Accretion Of Discount On Marketable Securities NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities	-14382000
CY2022	verv	Net Amortization Of Premium Accretion Of Discount On Marketable Securities NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities	-1027000
CY2021	verv	Net Amortization Of Premium Accretion Of Discount On Marketable Securities NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities	1508000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	35116000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	22477000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	7072000
CY2023	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	0
CY2022	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	0
CY2021	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	25574000
CY2023	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	-165000
CY2022	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	-1486000
CY2021	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	7815000
CY2023	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	5892000
CY2022	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	1012000
CY2021	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	0
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1406000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9436000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7528000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3910000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5216000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6829000
CY2023	verv	Issuance Costs Of Common Stock From Initial Public Offering IssuanceCostsOfCommonStockFromInitialPublicOffering	9013000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	134736000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	966000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35116000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-200068000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	599502000
CY2023	us-gaap	Profit Loss ProfitLoss	-200068000
CY2022	us-gaap	Profit Loss ProfitLoss	-157387000
CY2021	us-gaap	Profit Loss ProfitLoss	-120314000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5455000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2804000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1535000
CY2023	us-gaap	Net Investment In Lease Credit Loss Expense Reversal NetInvestmentInLeaseCreditLossExpenseReversal	6792000
CY2022	us-gaap	Net Investment In Lease Credit Loss Expense Reversal NetInvestmentInLeaseCreditLossExpenseReversal	3907000
CY2021	us-gaap	Net Investment In Lease Credit Loss Expense Reversal NetInvestmentInLeaseCreditLossExpenseReversal	1842000
CY2023	verv	Net Amortization Of Premium Accretion Of Discount On Marketable Securities NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities	-14382000
CY2022	verv	Net Amortization Of Premium Accretion Of Discount On Marketable Securities NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities	-1027000
CY2021	verv	Net Amortization Of Premium Accretion Of Discount On Marketable Securities NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities	1508000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	35116000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	22477000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	7072000
CY2023	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	0
CY2022	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	0
CY2021	verv	Change In Fair Value Of Antidilution Rights ChangeInFairValueOfAntidilutionRights	25574000
CY2023	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	-165000
CY2022	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	-1486000
CY2021	verv	Change In Fair Value Of Success Payments Liabilities ChangeInFairValueOfSuccessPaymentsLiabilities	7815000
CY2023	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	5892000
CY2022	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	1012000
CY2021	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	0
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1406000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9436000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3910000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5216000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6829000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-231000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7041000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5977000
CY2023	verv	Success Of Payment Liability SuccessOfPaymentLiability	0
CY2022	verv	Success Of Payment Liability SuccessOfPaymentLiability	0
CY2021	verv	Success Of Payment Liability SuccessOfPaymentLiability	6250000
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	28542000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	20014000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-7220000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3011000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-231000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7041000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5977000
CY2023	verv	Success Of Payment Liability SuccessOfPaymentLiability	0
CY2022	verv	Success Of Payment Liability SuccessOfPaymentLiability	0
CY2021	verv	Success Of Payment Liability SuccessOfPaymentLiability	6250000
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	28542000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	20014000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-7220000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1940000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-149549000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-122332000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-77880000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9283000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13232000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4359000
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	517140000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	479401000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	371494000
CY2023	verv	Maturities Of Marketable Securities MaturitiesOfMarketableSecurities	554113000
CY2022	verv	Maturities Of Marketable Securities MaturitiesOfMarketableSecurities	336678000
CY2021	verv	Maturities Of Marketable Securities MaturitiesOfMarketableSecurities	136755000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27690000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-155955000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-239098000
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	93759000
CY2023	verv	Proceeds From Issuance Of Common Shares Net Of Commissions ProceedsFromIssuanceOfCommonSharesNetOfCommissions	178746000
CY2022	verv	Proceeds From Issuance Of Common Shares Net Of Commissions ProceedsFromIssuanceOfCommonSharesNetOfCommissions	286509000
CY2021	verv	Proceeds From Issuance Of Common Shares Net Of Commissions ProceedsFromIssuanceOfCommonSharesNetOfCommissions	285214000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	31710000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	39986000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2023	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	458000
CY2022	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	783000
CY2021	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3630000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1200000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2175000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	966000
CY2023	us-gaap	Employee Stock Ownership Plan Esop Cash Contributions To Esop EmployeeStockOwnershipPlanESOPCashContributionsToESOP	1379000
CY2022	us-gaap	Employee Stock Ownership Plan Esop Cash Contributions To Esop EmployeeStockOwnershipPlanESOPCashContributionsToESOP	1069000
CY2021	us-gaap	Employee Stock Ownership Plan Esop Cash Contributions To Esop EmployeeStockOwnershipPlanESOPCashContributionsToESOP	780000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	212577000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	328956000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1940000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-149549000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-122332000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-77880000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9283000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13232000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4359000
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	517140000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	479401000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	371494000
CY2023	verv	Maturities Of Marketable Securities MaturitiesOfMarketableSecurities	554113000
CY2022	verv	Maturities Of Marketable Securities MaturitiesOfMarketableSecurities	336678000
CY2021	verv	Maturities Of Marketable Securities MaturitiesOfMarketableSecurities	136755000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27690000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-155955000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-239098000
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	93759000
CY2023	verv	Proceeds From Issuance Of Common Shares Net Of Commissions ProceedsFromIssuanceOfCommonSharesNetOfCommissions	178746000
CY2022	verv	Proceeds From Issuance Of Common Shares Net Of Commissions ProceedsFromIssuanceOfCommonSharesNetOfCommissions	286509000
CY2021	verv	Proceeds From Issuance Of Common Shares Net Of Commissions ProceedsFromIssuanceOfCommonSharesNetOfCommissions	285214000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	31710000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	39986000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2023	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	458000
CY2022	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	783000
CY2021	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3630000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1200000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2175000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	966000
CY2023	us-gaap	Employee Stock Ownership Plan Esop Cash Contributions To Esop EmployeeStockOwnershipPlanESOPCashContributionsToESOP	1379000
CY2022	us-gaap	Employee Stock Ownership Plan Esop Cash Contributions To Esop EmployeeStockOwnershipPlanESOPCashContributionsToESOP	1069000
CY2021	us-gaap	Employee Stock Ownership Plan Esop Cash Contributions To Esop EmployeeStockOwnershipPlanESOPCashContributionsToESOP	780000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	212577000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	328956000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	377089000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	90718000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	50669000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	60111000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120236000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69567000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9456000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	210954000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120236000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69567000
CY2023	verv	Property And Equipment Additions Included In Accounts Payable And Accrued Expenses PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses	1534000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	377089000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	90718000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	50669000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	60111000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120236000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69567000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9456000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	210954000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120236000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69567000
CY2023	verv	Property And Equipment Additions Included In Accounts Payable And Accrued Expenses PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses	1534000
CY2022	verv	Property And Equipment Additions Included In Accounts Payable And Accrued Expenses PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses	1706000
CY2021	verv	Property And Equipment Additions Included In Accounts Payable And Accrued Expenses PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses	503000
CY2023	verv	Financing Costs Included In Accounts Payable And Accrued Expenses FinancingCostsIncludedInAccountsPayableAndAccruedExpenses	21000
CY2022	verv	Financing Costs Included In Accounts Payable And Accrued Expenses FinancingCostsIncludedInAccountsPayableAndAccruedExpenses	0
CY2021	verv	Financing Costs Included In Accounts Payable And Accrued Expenses FinancingCostsIncludedInAccountsPayableAndAccruedExpenses	0
CY2023	verv	Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering	0
CY2022	verv	Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering	0
CY2021	verv	Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering	218919000
CY2023	verv	Settlement Of Antidilution Rights Liability By Issuing Common Stock SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock	0
CY2022	verv	Settlement Of Antidilution Rights Liability By Issuing Common Stock SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock	0
CY2021	verv	Settlement Of Antidilution Rights Liability By Issuing Common Stock SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock	32490000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	83417000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	809000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Nature of the business and basis of presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Organization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Verve Therapeutics, Inc. (the “Company” or “Verve”) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The Company was incorporated on March 9, 2018 as Endcadia, Inc., a Delaware corporation, and began operations shortly thereafter. In January 2019, the Company amended its certificate of incorporation to change its name to Verve Therapeutics, Inc. The Company’s principal offices are located in Boston, Massachusetts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Liquidity and capital resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company expects that its cash, cash equivalents and marketable securities of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">624.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> as of December 31, 2023, will be sufficient to fund its operations and capital expenditure requirements beyond the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company’s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Basis of presentation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	624000000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">assumptions </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">on historical experience when available and on various factors that it believes to be reasonable under the circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2022	verv	Property And Equipment Additions Included In Accounts Payable And Accrued Expenses PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses	1706000
CY2021	verv	Property And Equipment Additions Included In Accounts Payable And Accrued Expenses PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses	503000
CY2023	verv	Financing Costs Included In Accounts Payable And Accrued Expenses FinancingCostsIncludedInAccountsPayableAndAccruedExpenses	21000
CY2022	verv	Financing Costs Included In Accounts Payable And Accrued Expenses FinancingCostsIncludedInAccountsPayableAndAccruedExpenses	0
CY2021	verv	Financing Costs Included In Accounts Payable And Accrued Expenses FinancingCostsIncludedInAccountsPayableAndAccruedExpenses	0
CY2023	verv	Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering	0
CY2022	verv	Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering	0
CY2021	verv	Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering	218919000
CY2023	verv	Settlement Of Antidilution Rights Liability By Issuing Common Stock SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock	0
CY2022	verv	Settlement Of Antidilution Rights Liability By Issuing Common Stock SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock	0
CY2021	verv	Settlement Of Antidilution Rights Liability By Issuing Common Stock SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock	32490000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	83417000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	809000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Nature of the business and basis of presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Organization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Verve Therapeutics, Inc. (the “Company” or “Verve”) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The Company was incorporated on March 9, 2018 as Endcadia, Inc., a Delaware corporation, and began operations shortly thereafter. In January 2019, the Company amended its certificate of incorporation to change its name to Verve Therapeutics, Inc. The Company’s principal offices are located in Boston, Massachusetts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Liquidity and capital resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company expects that its cash, cash equivalents and marketable securities of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">624.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> as of December 31, 2023, will be sufficient to fund its operations and capital expenditure requirements beyond the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company’s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Basis of presentation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	624000000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">assumptions </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">on historical experience when available and on various factors that it believes to be reasonable under the circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>

CY2023

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

FY

CY2023

dei

Amendment Flag

AmendmentFlag

false

CY2023

dei

Entity Central Index Key

EntityCentralIndexKey

0001840574

CY2023

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

CY2023Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

CY2022Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

CY2023

dei

Document Type

DocumentType

10-K

CY2023

dei

Document Annual Report

DocumentAnnualReport

true

CY2023

dei

Document Period End Date

DocumentPeriodEndDate

2023-12-31

CY2023

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2023

CY2023

dei

Document Transition Report

DocumentTransitionReport

false

CY2023

dei

Entity File Number

EntityFileNumber

001-40489

CY2023

dei

Entity Registrant Name

EntityRegistrantName

VERVE THERAPEUTICS, INC.

CY2023

dei

Entity Incorporation State Country Code

EntityIncorporationStateCountryCode

DE

CY2023

dei

Entity Tax Identification Number

EntityTaxIdentificationNumber

82-4800132

CY2023

dei

Entity Address Address Line1

EntityAddressAddressLine1

201 Brookline Avenue, Suite 601

CY2023

dei

Entity Address City Or Town

EntityAddressCityOrTown

Boston

CY2023

dei

Entity Address State Or Province

EntityAddressStateOrProvince

MA

CY2023

dei

Entity Address Postal Zip Code

EntityAddressPostalZipCode

02215

CY2023

dei

City Area Code

CityAreaCode

617

CY2023

dei

Local Phone Number

LocalPhoneNumber

603-0070

CY2023

dei

Security12b Title

Security12bTitle

Common stock, par value $0.001 per share

CY2023

dei

Trading Symbol

TradingSymbol

VERV

CY2023

dei

Security Exchange Name

SecurityExchangeName

NASDAQ

CY2023

dei

Entity Well Known Seasoned Issuer

EntityWellKnownSeasonedIssuer

Yes

CY2023

dei

Entity Voluntary Filers

EntityVoluntaryFilers

No

CY2023

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

CY2023

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

CY2023

dei

Entity Filer Category

EntityFilerCategory

Large Accelerated Filer

CY2023

dei

Entity Small Business

EntitySmallBusiness

true

CY2023

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

CY2023

dei

Icfr Auditor Attestation Flag

IcfrAuditorAttestationFlag

true

CY2023

dei

Document Fin Stmt Error Correction Flag

DocumentFinStmtErrorCorrectionFlag

false

CY2023

dei

Entity Shell Company

EntityShellCompany

false

CY2023Q2

dei

Entity Public Float

EntityPublicFloat

939900000

CY2023Q4

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

83619279

CY2023

dei

Auditor Firm

AuditorFirmId

42

CY2023

dei

Auditor Name

AuditorName

Ernst & Young LLP

CY2023

dei

Auditor Location

AuditorLocation

Boston, Massachusetts

CY2023Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

206180000

CY2022Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

115412000

CY2023Q4

us-gaap

Marketable Securities Current

MarketableSecuritiesCurrent

417770000

CY2022Q4

us-gaap

Marketable Securities Current

MarketableSecuritiesCurrent

439396000

CY2023Q4

verv

Collaboration Receivable

CollaborationReceivable

5897000

CY2022Q4

verv

Collaboration Receivable

CollaborationReceivable

1012000

CY2023Q4

us-gaap

Prepaid Expense And Other Assets Current

PrepaidExpenseAndOtherAssetsCurrent

8102000

CY2022Q4

us-gaap

Prepaid Expense And Other Assets Current

PrepaidExpenseAndOtherAssetsCurrent

7339000

CY2023Q4

us-gaap

Assets Current

AssetsCurrent

637949000

CY2022Q4

us-gaap

Assets Current

AssetsCurrent

563159000

CY2023Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

22505000

CY2022Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

18778000

CY2023Q4

us-gaap

Restricted Cash Noncurrent

RestrictedCashNoncurrent

4774000

CY2022Q4

us-gaap

Restricted Cash Noncurrent

RestrictedCashNoncurrent

4824000

CY2023Q4

us-gaap

Operating Lease Right Of Use Asset

OperatingLeaseRightOfUseAsset

85295000

CY2022Q4

us-gaap

Operating Lease Right Of Use Asset

OperatingLeaseRightOfUseAsset

91877000

CY2023Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

2165000

CY2022Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

585000

CY2023Q4

us-gaap

Assets

752688000

CY2022Q4

us-gaap

Assets

679223000

CY2023Q4

us-gaap

Accounts Payable Current

AccountsPayableCurrent

6636000

CY2022Q4

us-gaap

Accounts Payable Current

AccountsPayableCurrent

2424000

CY2023Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

20178000

CY2022Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

20767000

CY2023Q4

us-gaap

Operating Lease Liability Current

OperatingLeaseLiabilityCurrent

10192000

CY2022Q4

us-gaap

Operating Lease Liability Current

OperatingLeaseLiabilityCurrent

11904000

CY2023Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

37006000

CY2022Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

35095000

CY2023Q4

us-gaap

Operating Lease Liability Noncurrent

OperatingLeaseLiabilityNoncurrent

64715000

CY2022Q4

us-gaap

Operating Lease Liability Noncurrent

OperatingLeaseLiabilityNoncurrent

70014000

CY2023Q4

verv

Success Payment Liability

SuccessPaymentLiability

2720000

CY2022Q4

verv

Success Payment Liability

SuccessPaymentLiability

2885000

CY2023Q4

us-gaap

Deferred Revenue And Credits Noncurrent

DeferredRevenueAndCreditsNoncurrent

48556000

CY2022Q4

us-gaap

Deferred Revenue And Credits Noncurrent

DeferredRevenueAndCreditsNoncurrent

20014000

CY2023Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

189000

CY2022Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

283000

CY2023Q4

us-gaap

Liabilities

153186000

CY2022Q4

us-gaap

Liabilities

128291000

CY2023Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.001

CY2022Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.001

CY2023Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

5000000

CY2022Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

5000000

CY2023Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

CY2022Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

CY2023Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

CY2022Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

CY2023Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

CY2022Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

CY2023Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2022Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2023Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

200000000

CY2022Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

200000000

CY2023Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

81969693

CY2023Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

81969693

CY2022Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

61730816

CY2022Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

61730816

CY2023Q4

us-gaap

Common Stock Value

CommonStockValue

82000

CY2022Q4

us-gaap

Common Stock Value

CommonStockValue

62000

CY2023Q4

us-gaap

Additional Paid In Capital Common Stock

AdditionalPaidInCapitalCommonStock

1143453000

CY2022Q4

us-gaap

Additional Paid In Capital Common Stock

AdditionalPaidInCapitalCommonStock

895801000

CY2023Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

272000

CY2022Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-694000

CY2023Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-544305000

CY2022Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-344237000

CY2023Q4

us-gaap

Stockholders Equity

StockholdersEquity

599502000

CY2022Q4

us-gaap

Stockholders Equity

StockholdersEquity

550932000

CY2023Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

752688000

CY2022Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

679223000

CY2023

verv

Collaborations Revenue

CollaborationsRevenue

11758000

CY2022

verv

Collaborations Revenue

CollaborationsRevenue

1941000

CY2021

verv

Collaborations Revenue

CollaborationsRevenue

0

CY2023

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

184946000

CY2022

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

130095000

CY2021

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

68202000

CY2023

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

49936000

CY2022

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

37533000

CY2021

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

18865000

CY2023

us-gaap

Operating Expenses

OperatingExpenses

234882000

CY2022

us-gaap

Operating Expenses

OperatingExpenses

167628000

CY2021

us-gaap

Operating Expenses

OperatingExpenses

87067000

CY2023

us-gaap

Operating Income Loss

OperatingIncomeLoss

-223124000

CY2022

us-gaap

Operating Income Loss

OperatingIncomeLoss

-165687000

CY2021

us-gaap

Operating Income Loss

OperatingIncomeLoss

-87067000

CY2023

verv

Change In Fair Value Of Antidilution Rights

ChangeInFairValueOfAntidilutionRights

0

CY2022

verv

Change In Fair Value Of Antidilution Rights

ChangeInFairValueOfAntidilutionRights

0

CY2021

verv

Change In Fair Value Of Antidilution Rights

ChangeInFairValueOfAntidilutionRights

25574000

CY2023

verv

Change In Fair Value Of Success Payments Liabilities

ChangeInFairValueOfSuccessPaymentsLiabilities

-165000

CY2022

verv

Change In Fair Value Of Success Payments Liabilities

ChangeInFairValueOfSuccessPaymentsLiabilities

-1486000

CY2021

verv

Change In Fair Value Of Success Payments Liabilities

ChangeInFairValueOfSuccessPaymentsLiabilities

7815000

CY2023

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

23166000

CY2022

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

6867000

CY2021

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

142000

CY2023

us-gaap

Nonoperating Income Expense

NonoperatingIncomeExpense

23331000

CY2022

us-gaap

Nonoperating Income Expense

NonoperatingIncomeExpense

8353000

CY2023Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

81969693

CY2022Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

61730816

CY2022Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

61730816

CY2023Q4

us-gaap

Common Stock Value

CommonStockValue

82000

CY2022Q4

us-gaap

Common Stock Value

CommonStockValue

62000

CY2023Q4

us-gaap

Additional Paid In Capital Common Stock

AdditionalPaidInCapitalCommonStock

1143453000

CY2022Q4

us-gaap

Additional Paid In Capital Common Stock

AdditionalPaidInCapitalCommonStock

895801000

CY2023Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

272000

CY2022Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-694000

CY2022Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

679223000

CY2023

verv

Collaborations Revenue

CollaborationsRevenue

11758000

CY2021

verv

Collaborations Revenue

CollaborationsRevenue

0

CY2023

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

184946000

CY2022

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

130095000

CY2021

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

68202000

CY2021

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

18865000

CY2023

us-gaap

Operating Expenses

OperatingExpenses

234882000

CY2022

us-gaap

Operating Expenses

OperatingExpenses

167628000

CY2021

us-gaap

Operating Expenses

OperatingExpenses

87067000

CY2023

us-gaap

Operating Income Loss

OperatingIncomeLoss

-223124000

CY2022

us-gaap

Operating Income Loss

OperatingIncomeLoss

-165687000

CY2021

us-gaap

Operating Income Loss

OperatingIncomeLoss

-87067000

CY2023

verv

Change In Fair Value Of Antidilution Rights

ChangeInFairValueOfAntidilutionRights

0

CY2022

verv

Change In Fair Value Of Antidilution Rights

ChangeInFairValueOfAntidilutionRights

0

CY2021

verv

Change In Fair Value Of Antidilution Rights

ChangeInFairValueOfAntidilutionRights

25574000

CY2023

verv

Change In Fair Value Of Success Payments Liabilities

ChangeInFairValueOfSuccessPaymentsLiabilities

-165000

CY2022

verv

Change In Fair Value Of Success Payments Liabilities

ChangeInFairValueOfSuccessPaymentsLiabilities

-1486000

CY2021

verv

Change In Fair Value Of Success Payments Liabilities

ChangeInFairValueOfSuccessPaymentsLiabilities

7815000

CY2023

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

23166000

CY2022

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

6867000

CY2021

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

142000

CY2023

us-gaap

Nonoperating Income Expense

NonoperatingIncomeExpense

23331000

CY2022

us-gaap

Nonoperating Income Expense

NonoperatingIncomeExpense

8353000

CY2021

us-gaap

Nonoperating Income Expense

NonoperatingIncomeExpense

-33247000

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-199793000

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-157334000

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-120314000

CY2023

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

275000

CY2022

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

53000

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

0

CY2023

us-gaap

Net Income Loss

NetIncomeLoss

-200068000

CY2022

us-gaap

Net Income Loss

NetIncomeLoss

-157387000

CY2021

us-gaap

Net Income Loss

NetIncomeLoss

-120314000

CY2023

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-3.12

CY2023

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-3.12

CY2022

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-2.91

CY2021

us-gaap

Nonoperating Income Expense

NonoperatingIncomeExpense

-33247000

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-199793000

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-157334000

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

-120314000

CY2023

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

275000

CY2022

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

53000

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

0

CY2023

us-gaap

Net Income Loss

NetIncomeLoss

-200068000

CY2022

us-gaap

Net Income Loss

NetIncomeLoss

-157387000

CY2021

us-gaap

Net Income Loss

NetIncomeLoss

-120314000

CY2023

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-3.12

CY2022

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-2.91

CY2021

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-4.48

CY2021

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-4.48

CY2023

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

64175137

CY2023

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

64175137

CY2022

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

54023653

CY2022

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

54023653

CY2021

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

26872036

CY2021

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

26872036

CY2023

us-gaap

Net Income Loss

NetIncomeLoss

-200068000

CY2022

us-gaap

Net Income Loss

NetIncomeLoss

-157387000

CY2021

us-gaap

Net Income Loss

NetIncomeLoss

-120314000

CY2023

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

966000

CY2022

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-466000

CY2023

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-199102000

CY2022

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-157853000

CY2021

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-120550000

CY2020Q4

us-gaap

Stockholders Equity

StockholdersEquity

-63909000

CY2021

verv

Issuance Costs Of Series B Convertible Preferred Stock

IssuanceCostsOfSeriesBConvertiblePreferredStock

241000

CY2021

us-gaap

Stock Issued During Period Value Conversion Of Convertible Securities

StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

218919000

CY2021

verv

Issuance Costs Of Common Stock From Initial Public Offering

IssuanceCostsOfCommonStockFromInitialPublicOffering

25098000

CY2021

us-gaap

Stock Issued During Period Value New Issues

StockIssuedDuringPeriodValueNewIssues

281584000

CY2021

verv

Stock Issued During Period Value Licensor Institutions

StockIssuedDuringPeriodValueLicensorInstitutions

32490000

CY2021

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

966000

CY2021

us-gaap

Stock Issued During Period Value Employee Stock Purchase Plan

StockIssuedDuringPeriodValueEmployeeStockPurchasePlan

780000

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

-236000

CY2021

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

7072000

CY2021

us-gaap

Net Income Loss

NetIncomeLoss

-120314000

CY2021Q4

us-gaap

Stockholders Equity

StockholdersEquity

357352000

CY2022

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

2175000

CY2022

us-gaap

Stock Issued During Period Value Employee Stock Purchase Plan

StockIssuedDuringPeriodValueEmployeeStockPurchasePlan

1069000

CY2022

verv

Stock Issued During Period Value Licensor Institutions

StockIssuedDuringPeriodValueLicensorInstitutions

39986000

CY2022

verv

Issuance Costs Of Common Stock From Initial Public Offering

IssuanceCostsOfCommonStockFromInitialPublicOffering

15924000

CY2022

us-gaap

Stock Issued During Period Value New Issues

StockIssuedDuringPeriodValueNewIssues

242826000

CY2022

verv

Issuance Of Common Stock From At The Market Offering

IssuanceOfCommonStockFromAtTheMarketOffering

1722000000

CY2022

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-2.91

CY2021

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-4.48

CY2021

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-4.48

CY2023

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

64175137

CY2023

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

64175137

CY2022

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

54023653

CY2022

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

54023653

CY2021

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

26872036

CY2021

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

26872036

CY2023

us-gaap

Net Income Loss

NetIncomeLoss

-200068000

CY2022

us-gaap

Net Income Loss

NetIncomeLoss

-157387000

CY2021

us-gaap

Net Income Loss

NetIncomeLoss

-120314000

CY2023

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

966000

CY2022

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-466000

CY2021

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-236000

CY2023

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-199102000

CY2022

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-157853000

CY2021

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

-120550000

CY2020Q4

us-gaap

Stockholders Equity

StockholdersEquity

-63909000

CY2021

verv

Issuance Costs Of Series B Convertible Preferred Stock

IssuanceCostsOfSeriesBConvertiblePreferredStock

241000

CY2021

us-gaap

Stock Issued During Period Value Conversion Of Convertible Securities

StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

218919000

CY2021

verv

Issuance Costs Of Common Stock From Initial Public Offering

IssuanceCostsOfCommonStockFromInitialPublicOffering

25098000

CY2021

us-gaap

Stock Issued During Period Value New Issues

StockIssuedDuringPeriodValueNewIssues

281584000

CY2021

verv

Stock Issued During Period Value Licensor Institutions

StockIssuedDuringPeriodValueLicensorInstitutions

32490000

CY2021

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

966000

CY2021

us-gaap

Stock Issued During Period Value Employee Stock Purchase Plan

StockIssuedDuringPeriodValueEmployeeStockPurchasePlan

780000

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

-236000

CY2021

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

7072000

CY2021

us-gaap

Net Income Loss

NetIncomeLoss

-120314000

CY2021Q4

us-gaap

Stockholders Equity

StockholdersEquity

357352000

CY2022

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

2175000

CY2022

us-gaap

Stock Issued During Period Value Employee Stock Purchase Plan

StockIssuedDuringPeriodValueEmployeeStockPurchasePlan

1069000

CY2022

verv

Stock Issued During Period Value Licensor Institutions

StockIssuedDuringPeriodValueLicensorInstitutions

39986000

CY2022

verv

Issuance Costs Of Common Stock From Initial Public Offering

IssuanceCostsOfCommonStockFromInitialPublicOffering

15924000

CY2022

us-gaap

Stock Issued During Period Value New Issues

StockIssuedDuringPeriodValueNewIssues

242826000

CY2022

verv

Issuance Of Common Stock From At The Market Offering

IssuanceOfCommonStockFromAtTheMarketOffering

1722000000

CY2022

verv

Issuance Of Common Stock From At The Market Offering Net Of Issuance Costs

IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts

42900000

CY2022

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

-466000

CY2022

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

22477000

CY2022

us-gaap

Net Income Loss

NetIncomeLoss

-157387000

CY2022Q4

us-gaap

Stockholders Equity

StockholdersEquity

550932000

CY2023

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

1200000

CY2023

us-gaap

Stock Issued During Period Value Employee Stock Purchase Plan

StockIssuedDuringPeriodValueEmployeeStockPurchasePlan

1379000

CY2023

verv

Issuance Of Common Stock In Connection With The Lilly Agreement

IssuanceOfCommonStockInConnectionWithTheLillyAgreement

54671000

CY2023

verv

Issuance Of Common Stock From At The Market Offering

IssuanceOfCommonStockFromAtTheMarketOffering

728000000

CY2023

verv

Issuance Of Common Stock From At The Market Offering Net Of Issuance Costs

IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts

20570000

CY2022

verv

Issuance Of Common Stock From At The Market Offering Net Of Issuance Costs

IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts

42900000

CY2022

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

-466000

CY2022

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

22477000

CY2022

us-gaap

Net Income Loss

NetIncomeLoss

-157387000

CY2022Q4

us-gaap

Stockholders Equity

StockholdersEquity

550932000

CY2023

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

1200000

CY2023

us-gaap

Stock Issued During Period Value Employee Stock Purchase Plan

StockIssuedDuringPeriodValueEmployeeStockPurchasePlan

1379000

CY2023

verv

Issuance Of Common Stock In Connection With The Lilly Agreement

IssuanceOfCommonStockInConnectionWithTheLillyAgreement

54671000

CY2023

verv

Issuance Of Common Stock From At The Market Offering

IssuanceOfCommonStockFromAtTheMarketOffering

728000000

CY2023

verv

Issuance Of Common Stock From At The Market Offering Net Of Issuance Costs

IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts

20570000

CY2023

verv

Issuance Costs Of Common Stock From Initial Public Offering

IssuanceCostsOfCommonStockFromInitialPublicOffering

9013000

CY2023

us-gaap

Stock Issued During Period Value New Issues

StockIssuedDuringPeriodValueNewIssues

134736000

CY2023

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

966000

CY2023

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

35116000

CY2020

us-gaap

Net Income Loss

NetIncomeLoss

-200068000

CY2023Q4

us-gaap

Stockholders Equity

StockholdersEquity

599502000

CY2023

us-gaap

Profit Loss

ProfitLoss

-200068000

CY2022

us-gaap

Profit Loss

ProfitLoss

-157387000

CY2021

us-gaap

Profit Loss

ProfitLoss

-120314000

CY2023

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

5455000

CY2022

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

2804000

CY2021

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

1535000

CY2023

us-gaap

Net Investment In Lease Credit Loss Expense Reversal

NetInvestmentInLeaseCreditLossExpenseReversal

6792000

CY2022

us-gaap

Net Investment In Lease Credit Loss Expense Reversal

NetInvestmentInLeaseCreditLossExpenseReversal

3907000

CY2021

us-gaap

Net Investment In Lease Credit Loss Expense Reversal

NetInvestmentInLeaseCreditLossExpenseReversal

1842000

CY2023

verv

Net Amortization Of Premium Accretion Of Discount On Marketable Securities

NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities

-14382000

CY2022

verv

Net Amortization Of Premium Accretion Of Discount On Marketable Securities

NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities

-1027000

CY2021

verv

Net Amortization Of Premium Accretion Of Discount On Marketable Securities

NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities

1508000

CY2023

us-gaap

Share Based Compensation

ShareBasedCompensation

35116000

CY2022

us-gaap

Share Based Compensation

ShareBasedCompensation

22477000

CY2021

us-gaap

Share Based Compensation

ShareBasedCompensation

7072000

CY2023

verv

Change In Fair Value Of Antidilution Rights

ChangeInFairValueOfAntidilutionRights

0

CY2022

verv

Change In Fair Value Of Antidilution Rights

ChangeInFairValueOfAntidilutionRights

0

CY2021

verv

Change In Fair Value Of Antidilution Rights

ChangeInFairValueOfAntidilutionRights

25574000

CY2023

verv

Change In Fair Value Of Success Payments Liabilities

ChangeInFairValueOfSuccessPaymentsLiabilities

-165000

CY2022

verv

Change In Fair Value Of Success Payments Liabilities

ChangeInFairValueOfSuccessPaymentsLiabilities

-1486000

CY2021

verv

Change In Fair Value Of Success Payments Liabilities

ChangeInFairValueOfSuccessPaymentsLiabilities

7815000

CY2023

us-gaap

Increase Decrease In Accounts Receivable Related Parties

IncreaseDecreaseInAccountsReceivableRelatedParties

5892000

CY2022

us-gaap

Increase Decrease In Accounts Receivable Related Parties

IncreaseDecreaseInAccountsReceivableRelatedParties

1012000

CY2021

us-gaap

Increase Decrease In Accounts Receivable Related Parties

IncreaseDecreaseInAccountsReceivableRelatedParties

0

CY2023

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

1406000

CY2022

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

9436000

CY2021

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

7528000

CY2023

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

3910000

CY2022

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

-5216000

CY2021

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

6829000

CY2023

verv

Issuance Costs Of Common Stock From Initial Public Offering

IssuanceCostsOfCommonStockFromInitialPublicOffering

9013000

CY2023

us-gaap

Stock Issued During Period Value New Issues

StockIssuedDuringPeriodValueNewIssues

134736000

CY2023

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

966000

CY2023

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

35116000

CY2020

us-gaap

Net Income Loss

NetIncomeLoss

-200068000

CY2023Q4

us-gaap

Stockholders Equity

StockholdersEquity

599502000

CY2023

us-gaap

Profit Loss

ProfitLoss

-200068000

CY2022

us-gaap

Profit Loss

ProfitLoss

-157387000

CY2021

us-gaap

Profit Loss

ProfitLoss

-120314000

CY2023

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

5455000

CY2022

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

2804000

CY2021

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

1535000

CY2023

us-gaap

Net Investment In Lease Credit Loss Expense Reversal

NetInvestmentInLeaseCreditLossExpenseReversal

6792000

CY2022

us-gaap

Net Investment In Lease Credit Loss Expense Reversal

NetInvestmentInLeaseCreditLossExpenseReversal

3907000

CY2021

us-gaap

Net Investment In Lease Credit Loss Expense Reversal

NetInvestmentInLeaseCreditLossExpenseReversal

1842000

CY2023

verv

Net Amortization Of Premium Accretion Of Discount On Marketable Securities

NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities

-14382000

CY2022

verv

Net Amortization Of Premium Accretion Of Discount On Marketable Securities

NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities

-1027000

CY2021

verv

Net Amortization Of Premium Accretion Of Discount On Marketable Securities

NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities

1508000

CY2023

us-gaap

Share Based Compensation

ShareBasedCompensation

35116000

CY2022

us-gaap

Share Based Compensation

ShareBasedCompensation

22477000

CY2021

us-gaap

Share Based Compensation

ShareBasedCompensation

7072000

CY2023

verv

Change In Fair Value Of Antidilution Rights

ChangeInFairValueOfAntidilutionRights

0

CY2022

verv

Change In Fair Value Of Antidilution Rights

ChangeInFairValueOfAntidilutionRights

0

CY2021

verv

Change In Fair Value Of Antidilution Rights

ChangeInFairValueOfAntidilutionRights

25574000

CY2023

verv

Change In Fair Value Of Success Payments Liabilities

ChangeInFairValueOfSuccessPaymentsLiabilities

-165000

CY2022

verv

Change In Fair Value Of Success Payments Liabilities

ChangeInFairValueOfSuccessPaymentsLiabilities

-1486000

CY2021

verv

Change In Fair Value Of Success Payments Liabilities

ChangeInFairValueOfSuccessPaymentsLiabilities

7815000

CY2023

us-gaap

Increase Decrease In Accounts Receivable Related Parties

IncreaseDecreaseInAccountsReceivableRelatedParties

5892000

CY2022

us-gaap

Increase Decrease In Accounts Receivable Related Parties

IncreaseDecreaseInAccountsReceivableRelatedParties

1012000

CY2021

us-gaap

Increase Decrease In Accounts Receivable Related Parties

IncreaseDecreaseInAccountsReceivableRelatedParties

0

CY2023

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

1406000

CY2022

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

9436000

CY2023

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

3910000

CY2022

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

-5216000

CY2021

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

6829000

CY2023

us-gaap

Increase Decrease In Accrued Liabilities And Other Operating Liabilities

IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

-231000

CY2022

us-gaap

Increase Decrease In Accrued Liabilities And Other Operating Liabilities

IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

7041000

CY2021

us-gaap

Increase Decrease In Accrued Liabilities And Other Operating Liabilities

IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

5977000

CY2023

verv

Success Of Payment Liability

SuccessOfPaymentLiability

0

CY2022

verv

Success Of Payment Liability

SuccessOfPaymentLiability

0

CY2021

verv

Success Of Payment Liability

SuccessOfPaymentLiability

6250000

CY2023

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

28542000

CY2022

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

20014000

CY2021

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

0

CY2023

us-gaap

Increase Decrease In Operating Lease Liability

IncreaseDecreaseInOperatingLeaseLiability

-7220000

CY2022

us-gaap

Increase Decrease In Operating Lease Liability

IncreaseDecreaseInOperatingLeaseLiability

-3011000

CY2023

us-gaap

Increase Decrease In Accrued Liabilities And Other Operating Liabilities

IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

-231000

CY2022

us-gaap

Increase Decrease In Accrued Liabilities And Other Operating Liabilities

IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

7041000

CY2021

us-gaap

Increase Decrease In Accrued Liabilities And Other Operating Liabilities

IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

5977000

CY2023

verv

Success Of Payment Liability

SuccessOfPaymentLiability

0

CY2022

verv

Success Of Payment Liability

SuccessOfPaymentLiability

0

CY2021

verv

Success Of Payment Liability

SuccessOfPaymentLiability

6250000

CY2023

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

28542000

CY2022

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

20014000

CY2021

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

0

CY2023

us-gaap

Increase Decrease In Operating Lease Liability

IncreaseDecreaseInOperatingLeaseLiability

-7220000

CY2021

us-gaap

Increase Decrease In Operating Lease Liability

IncreaseDecreaseInOperatingLeaseLiability

-1940000

CY2023

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

-149549000

CY2022

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

-122332000

CY2021

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

-77880000

CY2023

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

9283000

CY2022

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

13232000

CY2021

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

4359000

CY2023

us-gaap

Payments To Acquire Marketable Securities

PaymentsToAcquireMarketableSecurities

517140000

CY2022

us-gaap

Payments To Acquire Marketable Securities

PaymentsToAcquireMarketableSecurities

479401000

CY2021

us-gaap

Payments To Acquire Marketable Securities

PaymentsToAcquireMarketableSecurities

371494000

CY2023

verv

Maturities Of Marketable Securities

MaturitiesOfMarketableSecurities

554113000

CY2022

verv

Maturities Of Marketable Securities

MaturitiesOfMarketableSecurities

336678000

CY2021

verv

Maturities Of Marketable Securities

MaturitiesOfMarketableSecurities

136755000

CY2023

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

27690000

CY2022

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-155955000

CY2021

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-239098000

CY2023

us-gaap

Proceeds From Issuance Of Preferred Stock And Preference Stock

ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

0

CY2022

us-gaap

Proceeds From Issuance Of Preferred Stock And Preference Stock

ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

0

CY2021

us-gaap

Proceeds From Issuance Of Preferred Stock And Preference Stock

ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

93759000

CY2023

verv

Proceeds From Issuance Of Common Shares Net Of Commissions

ProceedsFromIssuanceOfCommonSharesNetOfCommissions

178746000

CY2022

verv

Proceeds From Issuance Of Common Shares Net Of Commissions

ProceedsFromIssuanceOfCommonSharesNetOfCommissions

286509000

CY2021

verv

Proceeds From Issuance Of Common Shares Net Of Commissions

ProceedsFromIssuanceOfCommonSharesNetOfCommissions

285214000

CY2023

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

31710000

CY2022

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

39986000

CY2021

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

0

CY2023

us-gaap

Payment Of Financing And Stock Issuance Costs

PaymentOfFinancingAndStockIssuanceCosts

458000

CY2022

us-gaap

Payment Of Financing And Stock Issuance Costs

PaymentOfFinancingAndStockIssuanceCosts

783000

CY2021

us-gaap

Payment Of Financing And Stock Issuance Costs

PaymentOfFinancingAndStockIssuanceCosts

3630000

CY2023

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

1200000

CY2022

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

2175000

CY2021

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

966000

CY2023

us-gaap

Employee Stock Ownership Plan Esop Cash Contributions To Esop

EmployeeStockOwnershipPlanESOPCashContributionsToESOP

1379000

CY2022

us-gaap

Employee Stock Ownership Plan Esop Cash Contributions To Esop

EmployeeStockOwnershipPlanESOPCashContributionsToESOP

1069000

CY2021

us-gaap

Employee Stock Ownership Plan Esop Cash Contributions To Esop

EmployeeStockOwnershipPlanESOPCashContributionsToESOP

780000

CY2023

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

212577000

CY2022

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

328956000

CY2021

us-gaap

Increase Decrease In Operating Lease Liability

IncreaseDecreaseInOperatingLeaseLiability

-1940000

CY2023

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

-149549000

CY2022

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

-122332000

CY2021

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

-77880000

CY2023

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

9283000

CY2022

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

13232000

CY2021

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

4359000

CY2023

us-gaap

Payments To Acquire Marketable Securities

PaymentsToAcquireMarketableSecurities

517140000

CY2022

us-gaap

Payments To Acquire Marketable Securities

PaymentsToAcquireMarketableSecurities

479401000

CY2021

us-gaap

Payments To Acquire Marketable Securities

PaymentsToAcquireMarketableSecurities

371494000

CY2023

verv

Maturities Of Marketable Securities

MaturitiesOfMarketableSecurities

554113000

CY2022

verv

Maturities Of Marketable Securities

MaturitiesOfMarketableSecurities

336678000

CY2021

verv

Maturities Of Marketable Securities

MaturitiesOfMarketableSecurities

136755000

CY2023

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

27690000

CY2022

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-155955000

CY2021

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-239098000

CY2023

us-gaap

Proceeds From Issuance Of Preferred Stock And Preference Stock

ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

0

CY2021

us-gaap

Proceeds From Issuance Of Preferred Stock And Preference Stock

ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

93759000

CY2023

verv

Proceeds From Issuance Of Common Shares Net Of Commissions

ProceedsFromIssuanceOfCommonSharesNetOfCommissions

178746000

CY2022

verv

Proceeds From Issuance Of Common Shares Net Of Commissions

ProceedsFromIssuanceOfCommonSharesNetOfCommissions

286509000

CY2021

verv

Proceeds From Issuance Of Common Shares Net Of Commissions

ProceedsFromIssuanceOfCommonSharesNetOfCommissions

285214000

CY2023

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

31710000

CY2022

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

39986000

CY2021

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

0

CY2023

us-gaap

Payment Of Financing And Stock Issuance Costs

PaymentOfFinancingAndStockIssuanceCosts

458000

CY2022

us-gaap

Payment Of Financing And Stock Issuance Costs

PaymentOfFinancingAndStockIssuanceCosts

783000

CY2021

us-gaap

Payment Of Financing And Stock Issuance Costs

PaymentOfFinancingAndStockIssuanceCosts

3630000

CY2023

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

1200000

CY2022

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

2175000

CY2021

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

966000

CY2023

us-gaap

Employee Stock Ownership Plan Esop Cash Contributions To Esop

EmployeeStockOwnershipPlanESOPCashContributionsToESOP

1379000

CY2022

us-gaap

Employee Stock Ownership Plan Esop Cash Contributions To Esop

EmployeeStockOwnershipPlanESOPCashContributionsToESOP

1069000

CY2021

us-gaap

Employee Stock Ownership Plan Esop Cash Contributions To Esop

EmployeeStockOwnershipPlanESOPCashContributionsToESOP

780000

CY2023

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

212577000

CY2022

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

328956000

CY2021

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

377089000

CY2023

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

90718000

CY2022

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

50669000

CY2021

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

60111000

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

120236000

CY2021Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

69567000

CY2020Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

9456000

CY2023Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

210954000

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

120236000

CY2021Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

69567000

CY2023

verv

Property And Equipment Additions Included In Accounts Payable And Accrued Expenses

PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses

1534000

CY2021

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

377089000

CY2023

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

90718000

CY2022

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

50669000

CY2021

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

60111000

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

120236000

CY2021Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

69567000

CY2020Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

9456000

CY2023Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

210954000

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

120236000

CY2021Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

69567000

CY2023

verv

Property And Equipment Additions Included In Accounts Payable And Accrued Expenses

PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses

1534000

CY2022

verv

Property And Equipment Additions Included In Accounts Payable And Accrued Expenses

PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses

1706000

CY2021

verv

Property And Equipment Additions Included In Accounts Payable And Accrued Expenses

PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses

503000

CY2023

verv

Financing Costs Included In Accounts Payable And Accrued Expenses

FinancingCostsIncludedInAccountsPayableAndAccruedExpenses

21000

CY2022

verv

Financing Costs Included In Accounts Payable And Accrued Expenses

FinancingCostsIncludedInAccountsPayableAndAccruedExpenses

0

CY2021

verv

Financing Costs Included In Accounts Payable And Accrued Expenses

FinancingCostsIncludedInAccountsPayableAndAccruedExpenses

0

CY2023

verv

Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering

TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering

0

CY2022

verv

Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering

TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering

0

CY2021

verv

Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering

TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering

218919000

CY2023

verv

Settlement Of Antidilution Rights Liability By Issuing Common Stock

SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock

0

CY2022

verv

Settlement Of Antidilution Rights Liability By Issuing Common Stock

SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock

0

CY2021

verv

Settlement Of Antidilution Rights Liability By Issuing Common Stock

SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock

32490000

CY2023

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

0

CY2022

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

83417000

CY2021

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

809000

CY2023

us-gaap

Nature Of Operations

NatureOfOperations

1. Nature of the business and basis of presentation Organization Verve Therapeutics, Inc. (the “Company” or “Verve”) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The Company was incorporated on March 9, 2018 as Endcadia, Inc., a Delaware corporation, and began operations shortly thereafter. In January 2019, the Company amended its certificate of incorporation to change its name to Verve Therapeutics, Inc. The Company’s principal offices are located in Boston, Massachusetts. Liquidity and capital resourcesSince its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company expects that its cash, cash equivalents and marketable securities of $624.0 million as of December 31, 2023, will be sufficient to fund its operations and capital expenditure requirements beyond the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company’s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so. Basis of presentationThe accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

CY2023Q4

us-gaap

Cash Cash Equivalents And Short Term Investments

CashCashEquivalentsAndShortTermInvestments

624000000

CY2023

us-gaap

Use Of Estimates

UseOfEstimates

Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances.

CY2022

verv

Property And Equipment Additions Included In Accounts Payable And Accrued Expenses

PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses

1706000

CY2021

verv

Property And Equipment Additions Included In Accounts Payable And Accrued Expenses

PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses

503000

CY2023

verv

Financing Costs Included In Accounts Payable And Accrued Expenses

FinancingCostsIncludedInAccountsPayableAndAccruedExpenses

21000

CY2022

verv

Financing Costs Included In Accounts Payable And Accrued Expenses

FinancingCostsIncludedInAccountsPayableAndAccruedExpenses

0

CY2021

verv

Financing Costs Included In Accounts Payable And Accrued Expenses

FinancingCostsIncludedInAccountsPayableAndAccruedExpenses

0

CY2023

verv

Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering

TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering

0

CY2022

verv

Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering

TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering

0

CY2021

verv

Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering

TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering

218919000

CY2023

verv

Settlement Of Antidilution Rights Liability By Issuing Common Stock

SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock

0

CY2022

verv

Settlement Of Antidilution Rights Liability By Issuing Common Stock

SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock

0

CY2021

verv

Settlement Of Antidilution Rights Liability By Issuing Common Stock

SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock

32490000

CY2023

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

0

CY2022

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

83417000

CY2021

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

809000

CY2023

us-gaap

Nature Of Operations

NatureOfOperations

1. Nature of the business and basis of presentation Organization Verve Therapeutics, Inc. (the “Company” or “Verve”) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The Company was incorporated on March 9, 2018 as Endcadia, Inc., a Delaware corporation, and began operations shortly thereafter. In January 2019, the Company amended its certificate of incorporation to change its name to Verve Therapeutics, Inc. The Company’s principal offices are located in Boston, Massachusetts. Liquidity and capital resourcesSince its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company expects that its cash, cash equivalents and marketable securities of $624.0 million as of December 31, 2023, will be sufficient to fund its operations and capital expenditure requirements beyond the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company’s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so. Basis of presentationThe accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

CY2023Q4

us-gaap

Cash Cash Equivalents And Short Term Investments

CashCashEquivalentsAndShortTermInvestments

624000000

CY2023

us-gaap

Use Of Estimates

UseOfEstimates

Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances.

CY2023Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

206180000

CY2022Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

115412000

CY2023Q4

us-gaap

Restricted Cash And Cash Equivalents At Carrying Value

RestrictedCashAndCashEquivalentsAtCarryingValue

4774000

CY2022Q4

us-gaap

Restricted Cash And Cash Equivalents At Carrying Value

RestrictedCashAndCashEquivalentsAtCarryingValue

4824000

CY2023Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

210954000

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

120236000

CY2023

us-gaap

Concentration Risk Credit Risk

ConcentrationRiskCreditRisk

Concentrations of credit risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, collaboration receivable, and restricted cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. The Company generally invests its excess capital in money market funds, U.S. treasury bills and agency securities, all of which are subject to minimal credit and market risk. The investment portfolio is maintained in accordance with the Company’s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer.

CY2023Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

206180000

CY2022Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

115412000

CY2023Q4

us-gaap

Restricted Cash And Cash Equivalents At Carrying Value

RestrictedCashAndCashEquivalentsAtCarryingValue

4774000

CY2022Q4

us-gaap

Restricted Cash And Cash Equivalents At Carrying Value

RestrictedCashAndCashEquivalentsAtCarryingValue

4824000

CY2023Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

210954000

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

120236000

CY2023

us-gaap

Concentration Risk Credit Risk

ConcentrationRiskCreditRisk

Concentrations of credit risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, collaboration receivable, and restricted cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. The Company generally invests its excess capital in money market funds, U.S. treasury bills and agency securities, all of which are subject to minimal credit and market risk. The investment portfolio is maintained in accordance with the Company’s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer.

CY2023

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

0

CY2022

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

0

CY2021

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

0

CY2023

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

0

CY2022

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

0

CY2021

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

0

CY2023Q4

verv

Percentage Of Tax Benefit Realized

PercentageOfTaxBenefitRealized

0.50

CY2023

us-gaap

Revenue Recognition Deferred Revenue

RevenueRecognitionDeferredRevenue

Revenue RecognitionThe Company enters into collaboration agreements which are within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), under which the Company licenses rights to certain of the Company’s product candidates and performs research and development services. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, regulatory, and commercial milestone payments; and royalties on net sales of licensed products.Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer. The promised goods or services in the Company’s arrangements typically consist of license rights to the Company’s intellectual property and research and development services. The Company provides options to additional items in the contracts, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the number of potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration which is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.The Company’s contracts often include development and regulatory milestone payments which are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment. To date, the Company has not recognized any consideration related to the achievement of development, regulatory, or commercial milestone revenue resulting from any of the Company’s collaboration arrangements.For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting from any of the Company’s collaboration arrangements.The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the Company utilizes comparable transactions, clinical trial success probabilities, and estimates of option exercise likelihood. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional.

CY2023

us-gaap

Revenue Recognition Deferred Revenue

RevenueRecognitionDeferredRevenue

Revenue RecognitionThe Company enters into collaboration agreements which are within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), under which the Company licenses rights to certain of the Company’s product candidates and performs research and development services. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, regulatory, and commercial milestone payments; and royalties on net sales of licensed products.Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer. The promised goods or services in the Company’s arrangements typically consist of license rights to the Company’s intellectual property and research and development services. The Company provides options to additional items in the contracts, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the number of potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration which is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.The Company’s contracts often include development and regulatory milestone payments which are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment. To date, the Company has not recognized any consideration related to the achievement of development, regulatory, or commercial milestone revenue resulting from any of the Company’s collaboration arrangements.For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting from any of the Company’s collaboration arrangements.The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the Company utilizes comparable transactions, clinical trial success probabilities, and estimates of option exercise likelihood. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional.

CY2023Q4

verv

Percentage Of Tax Benefit Realized

PercentageOfTaxBenefitRealized

0.50

CY2023

us-gaap

Number Of Operating Segments

NumberOfOperatingSegments

1

CY2022Q4

us-gaap

Debt Securities Available For Sale Amortized Cost Current

DebtSecuritiesAvailableForSaleAmortizedCostCurrent

440090000

CY2022Q4

verv

Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent

-775000

CY2023

us-gaap

Number Of Operating Segments

NumberOfOperatingSegments

1

CY2023Q4

us-gaap

Debt Securities Available For Sale Amortized Cost Current

DebtSecuritiesAvailableForSaleAmortizedCostCurrent

417498000

CY2023Q4

verv

Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent

421000

CY2023Q4

verv

Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent

-149000

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

417770000

CY2023Q4

us-gaap

Debt Securities Available For Sale Amortized Cost Current

DebtSecuritiesAvailableForSaleAmortizedCostCurrent

417498000

CY2023Q4

verv

Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent

421000

CY2023Q4

verv

Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent

-149000

CY2023Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

417770000

CY2022Q4

us-gaap

Debt Securities Available For Sale Amortized Cost Current

DebtSecuritiesAvailableForSaleAmortizedCostCurrent

440090000

CY2022Q4

verv

Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent

81000

CY2022Q4

verv

Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current

AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent

-775000

CY2022Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

439396000

CY2023

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

100000

CY2022

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

800000

CY2023

verv

Remaining Contractual Maturities Of Marketable Securities Term

RemainingContractualMaturitiesOfMarketableSecuritiesTerm

P12M

CY2022

verv

Remaining Contractual Maturities Of Marketable Securities Term

RemainingContractualMaturitiesOfMarketableSecuritiesTerm

P12M

CY2023Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

32897000

CY2022Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

23765000

CY2023Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

10392000

CY2022Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

4987000

CY2023Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

22505000

CY2022Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

18778000

CY2022Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

439396000

CY2023

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

100000

CY2022

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

800000

CY2023

verv

Remaining Contractual Maturities Of Marketable Securities Term

RemainingContractualMaturitiesOfMarketableSecuritiesTerm

P12M

CY2022

verv

Remaining Contractual Maturities Of Marketable Securities Term

RemainingContractualMaturitiesOfMarketableSecuritiesTerm

P12M

CY2023Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

32897000

CY2022Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

23765000

CY2023Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

10392000

CY2022Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

4987000

CY2023Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

22505000

CY2022Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

18778000

CY2023

us-gaap

Depreciation

5455000

CY2022

us-gaap

Depreciation

2804000

CY2021

us-gaap

Depreciation

1535000

CY2023Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

538757000

CY2023Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

2720000

CY2022Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

544699000

CY2022Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

2885000

CY2023Q4

us-gaap

Cash Equivalents At Carrying Value

CashEquivalentsAtCarryingValue

121000000

CY2022Q4

us-gaap

Cash Equivalents At Carrying Value

CashEquivalentsAtCarryingValue

105300000

CY2023Q4

verv

Fair Value Of Common Stock Per Share

FairValueOfCommonStockPerShare

13.94

CY2022Q4

verv

Fair Value Of Common Stock Per Share

FairValueOfCommonStockPerShare

19.35

CY2021Q4

verv

Fair Value Of Common Stock Per Share

FairValueOfCommonStockPerShare

36.87

CY2023

us-gaap

Depreciation

5455000

CY2022

us-gaap

Depreciation

2804000

CY2021

us-gaap

Depreciation

1535000

CY2023Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

538757000

CY2023Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

2720000

CY2022Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

544699000

CY2022Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

2885000

CY2023Q4

us-gaap

Cash Equivalents At Carrying Value

CashEquivalentsAtCarryingValue

121000000

CY2022Q4

us-gaap

Cash Equivalents At Carrying Value

CashEquivalentsAtCarryingValue

105300000

CY2023Q4

verv

Fair Value Of Common Stock Per Share

FairValueOfCommonStockPerShare

13.94

CY2022Q4

verv

Fair Value Of Common Stock Per Share

FairValueOfCommonStockPerShare

19.35

CY2021Q4

verv

Fair Value Of Common Stock Per Share

FairValueOfCommonStockPerShare

36.87

CY2023Q4

us-gaap

Accrued Employee Benefits Current

AccruedEmployeeBenefitsCurrent

12342000

CY2022Q4

us-gaap

Accrued Employee Benefits Current

AccruedEmployeeBenefitsCurrent

9124000

CY2023Q4

us-gaap

Accrued Employee Benefits Current

AccruedEmployeeBenefitsCurrent

12342000

CY2022Q4

us-gaap

Accrued Employee Benefits Current

AccruedEmployeeBenefitsCurrent

9124000

CY2023Q4

verv

Accrued External Research And Development Expenses

AccruedExternalResearchAndDevelopmentExpenses

4856000

CY2022Q4

verv

Accrued External Research And Development Expenses

AccruedExternalResearchAndDevelopmentExpenses

8919000

CY2023Q4

us-gaap

Accrued Professional Fees Current

AccruedProfessionalFeesCurrent

1492000

CY2022Q4

us-gaap

Accrued Professional Fees Current

AccruedProfessionalFeesCurrent

1193000

CY2023Q4

verv

License And Milestone Payments

LicenseAndMilestonePayments

500000

CY2022Q4

verv

License And Milestone Payments

LicenseAndMilestonePayments

310000

CY2023Q4

us-gaap

Other Accrued Liabilities Current

OtherAccruedLiabilitiesCurrent

988000

CY2022Q4

us-gaap

Other Accrued Liabilities Current

OtherAccruedLiabilitiesCurrent

1221000

CY2023Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

20178000

CY2022Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

20767000

CY2023

us-gaap

Operating Lease Cost

OperatingLeaseCost

12936000

CY2022

us-gaap

Operating Lease Cost

OperatingLeaseCost

5946000

CY2023

us-gaap

Variable Lease Cost

VariableLeaseCost

3854000

CY2022

us-gaap

Variable Lease Cost

VariableLeaseCost

1601000

CY2023

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

1259000

CY2022

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

698000

CY2023

us-gaap

Lease Cost

LeaseCost

18049000

CY2022

us-gaap

Lease Cost

LeaseCost

8245000

CY2023

us-gaap

Operating Lease Payments

OperatingLeasePayments

12550000

CY2022

us-gaap

Operating Lease Payments

OperatingLeasePayments

5050000

CY2023Q4

verv

Lessee Operating Lease Incremental Borrowing Rate

LesseeOperatingLeaseIncrementalBorrowingRate

0.0789

CY2023Q4

verv

Accrued External Research And Development Expenses

AccruedExternalResearchAndDevelopmentExpenses

4856000

CY2022Q4

verv

Accrued External Research And Development Expenses

AccruedExternalResearchAndDevelopmentExpenses

8919000

CY2023Q4

us-gaap

Accrued Professional Fees Current

AccruedProfessionalFeesCurrent

1492000

CY2022Q4

us-gaap

Accrued Professional Fees Current

AccruedProfessionalFeesCurrent

1193000

CY2023Q4

verv

License And Milestone Payments

LicenseAndMilestonePayments

500000

CY2022Q4

verv

License And Milestone Payments

LicenseAndMilestonePayments

310000

CY2023Q4

us-gaap

Other Accrued Liabilities Current

OtherAccruedLiabilitiesCurrent

988000

CY2022Q4

us-gaap

Other Accrued Liabilities Current

OtherAccruedLiabilitiesCurrent

1221000

CY2023Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

20178000

CY2022Q4

us-gaap

Accrued Liabilities Current

AccruedLiabilitiesCurrent

20767000

CY2023

us-gaap

Operating Lease Cost

OperatingLeaseCost

12936000

CY2022

us-gaap

Operating Lease Cost

OperatingLeaseCost

5946000

CY2023

us-gaap

Variable Lease Cost

VariableLeaseCost

3854000

CY2022

us-gaap

Variable Lease Cost

VariableLeaseCost

1601000

CY2023

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

1259000

CY2022

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

698000

CY2023

us-gaap

Lease Cost

LeaseCost

18049000

CY2022

us-gaap

Lease Cost

LeaseCost

8245000

CY2023

us-gaap

Operating Lease Payments

OperatingLeasePayments

12550000

CY2022

us-gaap

Operating Lease Payments

OperatingLeasePayments

5050000

CY2023Q4

verv

Lessee Operating Lease Incremental Borrowing Rate

LesseeOperatingLeaseIncrementalBorrowingRate

0.0789

CY2023Q4

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P9Y

CY2022Q3

verv

Increase Decrease In Operating Lease Right Of Use Of Asset

IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset

91800000

CY2022Q3

us-gaap

Increase Decrease In Operating Lease Liability

IncreaseDecreaseInOperatingLeaseLiability

80800000

CY2023

verv

Schedule Of Future Minimum Commitments Payments For Operating Leases Tabletextblock

ScheduleOfFutureMinimumCommitmentsPaymentsForOperatingLeasesTabletextblock

Future minimum commitments under non-cancellable leases as of December 31, 2023 were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;">Years ending December 31,</td> <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">Amount</td> <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">(in thousands)</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">2024</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">10,563</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">2025</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">10,868</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">2026</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">11,183</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">2027</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">11,506</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">2028</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">11,839</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Thereafter</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">50,075</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Total lease payments</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">106,034</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Less: interest</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">(31,127</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">)</td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;">Present value of operating lease liabilities</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">74,907</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> </table>

CY2023Q4

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P9Y

CY2022Q3

verv

Increase Decrease In Operating Lease Right Of Use Of Asset

IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset

91800000

CY2022Q3

us-gaap

Increase Decrease In Operating Lease Liability

IncreaseDecreaseInOperatingLeaseLiability

80800000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Payments Due Next Twelve Months

LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

10563000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Two

LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

10868000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Three

LesseeOperatingLeaseLiabilityPaymentsDueYearThree

11183000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Four

LesseeOperatingLeaseLiabilityPaymentsDueYearFour

11506000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Five

LesseeOperatingLeaseLiabilityPaymentsDueYearFive

11839000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Payments Due After Year Five

LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

50075000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Payments Due

LesseeOperatingLeaseLiabilityPaymentsDue

106034000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Undiscounted Excess Amount

LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

31127000

CY2023Q4

us-gaap

Operating Lease Liability

OperatingLeaseLiability

74907000

CY2022Q3

us-gaap

Payments To Acquire Commercial Real Estate

PaymentsToAcquireCommercialRealEstate

165000000

CY2022Q3

us-gaap

Investment Banking Advisory Brokerage And Underwriting Fees And Commissions

InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions

15800000

CY2022Q3

verv

Commission On Aggregate Gross Sale Proceeds

CommissionOnAggregateGrossSaleProceeds

0.03

CY2023

verv

Schedule Of Future Minimum Commitments Payments For Operating Leases Tabletextblock

ScheduleOfFutureMinimumCommitmentsPaymentsForOperatingLeasesTabletextblock

Future minimum commitments under non-cancellable leases as of December 31, 2023 were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;"></td> <td style="width:1.94%;"></td> <td style="width:1%;"></td> <td style="width:15.823%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;">Years ending December 31,</td> <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">Amount</td> <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">(in thousands)</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">2024</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">10,563</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">2025</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">10,868</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">2026</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">11,183</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">2027</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">11,506</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">2028</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">11,839</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Thereafter</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">50,075</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Total lease payments</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">106,034</td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">Less: interest</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">(31,127</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">)</td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;">Present value of operating lease liabilities</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">$</td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">74,907</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> </table>

CY2023Q4

us-gaap

Lessee Operating Lease Liability Payments Due Next Twelve Months

LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

10563000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Two

LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

10868000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Three

LesseeOperatingLeaseLiabilityPaymentsDueYearThree

11183000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Four

LesseeOperatingLeaseLiabilityPaymentsDueYearFour

11506000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Five

LesseeOperatingLeaseLiabilityPaymentsDueYearFive

11839000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Payments Due After Year Five

LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

50075000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Payments Due

LesseeOperatingLeaseLiabilityPaymentsDue

106034000

CY2023Q4

us-gaap

Lessee Operating Lease Liability Undiscounted Excess Amount

LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

31127000

CY2023Q4

us-gaap

Operating Lease Liability

OperatingLeaseLiability

74907000

CY2022Q3

us-gaap

Payments To Acquire Commercial Real Estate

PaymentsToAcquireCommercialRealEstate

165000000

CY2022Q3

us-gaap

Investment Banking Advisory Brokerage And Underwriting Fees And Commissions

InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions

15800000

CY2022Q3

verv

Commission On Aggregate Gross Sale Proceeds

CommissionOnAggregateGrossSaleProceeds

0.03

CY2023

us-gaap

Sale Of Stock Number Of Shares Issued In Transaction

SaleOfStockNumberOfSharesIssuedInTransaction

2780853

CY2023

us-gaap

Sale Of Stock Consideration Received On Transaction

SaleOfStockConsiderationReceivedOnTransaction

63500000

CY2023

us-gaap

Investment Banking Advisory Brokerage And Underwriting Fees And Commissions

InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions

9000000

CY2023Q4

us-gaap

Common Stock Capital Shares Reserved For Future Issuance

CommonStockCapitalSharesReservedForFutureIssuance

10144170

CY2023

us-gaap

Allocated Share Based Compensation Expense

AllocatedShareBasedCompensationExpense

35116000

CY2022

us-gaap

Allocated Share Based Compensation Expense

AllocatedShareBasedCompensationExpense

22477000

CY2021

us-gaap

Allocated Share Based Compensation Expense

AllocatedShareBasedCompensationExpense

7072000

CY2023

us-gaap

Sale Of Stock Number Of Shares Issued In Transaction

SaleOfStockNumberOfSharesIssuedInTransaction

2780853

CY2023

us-gaap

Sale Of Stock Consideration Received On Transaction

SaleOfStockConsiderationReceivedOnTransaction

63500000

CY2023

us-gaap

Investment Banking Advisory Brokerage And Underwriting Fees And Commissions

InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions

9000000

CY2023Q4

us-gaap

Common Stock Capital Shares Reserved For Future Issuance

CommonStockCapitalSharesReservedForFutureIssuance

10144170

CY2023

us-gaap

Allocated Share Based Compensation Expense

AllocatedShareBasedCompensationExpense

35116000

CY2022

us-gaap

Allocated Share Based Compensation Expense

AllocatedShareBasedCompensationExpense

22477000

CY2021

us-gaap

Allocated Share Based Compensation Expense

AllocatedShareBasedCompensationExpense

7072000

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.777

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.773

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.777

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.04

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.024

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.009

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P6Y

CY2022

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P6Y

CY2021

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P6Y

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

7612826

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

16.10

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

3152042

CY2023

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

19.83

CY2023

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

240182

CY2023

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

5.00

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

599808

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

25.57

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

9924878

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.777

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.773

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.777

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.04

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.024

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.009

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P6Y

CY2022

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P6Y

CY2021

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P6Y

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

7612826

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

16.10

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

3152042

CY2023

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

19.83

CY2023

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

240182

CY2023

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

5.00

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

599808

CY2023

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

25.57

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

9924878

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

16.98

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P7Y9M18D

CY2023Q4

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding

SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding

36695000

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

4549532

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice

12.49

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

P6Y10M24D

CY2023Q4

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

29820000

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

5375346

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

20.79

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

P8Y7M6D

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

6875000

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

16.98

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P7Y9M18D

CY2023Q4

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding

SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding

36695000

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

4549532

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice

12.49

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

P6Y10M24D

CY2023Q4

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

29820000

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

5375346

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

20.79

CY2023

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

P8Y7M6D

CY2023Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

6875000

CY2023

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-200068000

CY2022

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-157387000

CY2021

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-120314000

CY2023

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

64175137

CY2023

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

64175137

CY2022

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

54023653

CY2022

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

54023653

CY2021

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

26872036

CY2021

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

26872036

CY2023

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-3.12

CY2023

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-3.12

CY2022

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-2.91

CY2022

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-2.91

CY2021

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-4.48

CY2021

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-4.48

CY2023

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-200068000

CY2022

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-157387000

CY2021

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-120314000

CY2023

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

64175137

CY2023

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

64175137

CY2022

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

54023653

CY2022

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

54023653

CY2021

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

26872036

CY2021

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

26872036

CY2023

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-3.12

CY2023

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-3.12

CY2022

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-2.91

CY2022

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-2.91

CY2021

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-4.48

CY2021

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-4.48

CY2023

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

10889389

CY2022

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

8290651

CY2023

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

10889389

CY2022

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

8290651

CY2021

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

6151295

CY2023

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

199800000

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

157300000

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

120300000

CY2023

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

0

CY2022

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

0

CY2021

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

0

CY2023

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

275000

CY2021

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

0

CY2023

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

0

CY2022

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

0

CY2021

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

0

CY2023

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

275000

CY2022

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

53000

CY2021

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

0

CY2023

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

0

CY2022

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

0

CY2021

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

0

CY2023

us-gaap

Deferred State And Local Income Tax Expense Benefit

DeferredStateAndLocalIncomeTaxExpenseBenefit

0

CY2022

us-gaap

Deferred State And Local Income Tax Expense Benefit

DeferredStateAndLocalIncomeTaxExpenseBenefit

0

CY2021

us-gaap

Deferred State And Local Income Tax Expense Benefit

DeferredStateAndLocalIncomeTaxExpenseBenefit

0

CY2023

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

0

CY2022

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

0

CY2021

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

0

CY2021

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

6151295

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

157300000

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Domestic

IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

120300000

CY2023

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

0

CY2022

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

0

CY2021

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

0

CY2023

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

275000

CY2022

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

53000

CY2021

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

0

CY2023

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

0

CY2022

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

0

CY2021

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

0

CY2023

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

275000

CY2022

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

53000

CY2021

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

0

CY2023

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

0

CY2022

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

0

CY2021

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

0

CY2023

us-gaap

Deferred State And Local Income Tax Expense Benefit

DeferredStateAndLocalIncomeTaxExpenseBenefit

0

CY2022

us-gaap

Deferred State And Local Income Tax Expense Benefit

DeferredStateAndLocalIncomeTaxExpenseBenefit

0

CY2021

us-gaap

Deferred State And Local Income Tax Expense Benefit

DeferredStateAndLocalIncomeTaxExpenseBenefit

0

CY2023

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

0

CY2022

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

0

CY2021

us-gaap

Deferred Foreign Income Tax Expense Benefit

DeferredForeignIncomeTaxExpenseBenefit

0

CY2023

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

0

CY2022

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

0

CY2021

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

0

CY2023

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.21

CY2022

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.21

CY2021

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.21

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.313

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.347

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.313

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent

EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent

-0.01

CY2023

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

0

CY2022

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

0

CY2021

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

0

CY2023

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.21

CY2021

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.21

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.313

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.347

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

-0.313

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent

EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent

-0.01

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent

EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent

0.003

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent

EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent

0.009

CY2023

verv

Effective Income Tax Rate Reconciliation Executive Compensation Percent

EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent

-0.002

CY2022

verv

Effective Income Tax Rate Reconciliation Executive Compensation Percent

EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent

-0.008

CY2021

verv

Effective Income Tax Rate Reconciliation Executive Compensation Percent

EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent

-0.011

CY2023

verv

Effective Income Tax Rate Reconciliation Permanent Items

EffectiveIncomeTaxRateReconciliationPermanentItems

-0.001

CY2022

verv

Effective Income Tax Rate Reconciliation Permanent Items

EffectiveIncomeTaxRateReconciliationPermanentItems

-0.002

CY2021

verv

Effective Income Tax Rate Reconciliation Permanent Items

EffectiveIncomeTaxRateReconciliationPermanentItems

-0.001

CY2023

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.082

CY2022

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.084

CY2021

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.061

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment

0.036

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment

0.056

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment

0.045

CY2023

verv

Effective Income Tax Rate Reconciliation Other

EffectiveIncomeTaxRateReconciliationOther

-0.003

CY2022

verv

Effective Income Tax Rate Reconciliation Other

EffectiveIncomeTaxRateReconciliationOther

0.01

CY2021

verv

Effective Income Tax Rate Reconciliation Other

EffectiveIncomeTaxRateReconciliationOther

0

CY2023

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

-0.001

CY2022

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0

CY2021

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0

CY2023Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

51295000

CY2022Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

43779000

CY2023Q4

verv

Deferred Tax Assets Capitalized Costs Net Of Amortization

DeferredTaxAssetsCapitalizedCostsNetOfAmortization

10844000

CY2022Q4

verv

Deferred Tax Assets Capitalized Costs Net Of Amortization

DeferredTaxAssetsCapitalizedCostsNetOfAmortization

11095000

CY2023Q4

us-gaap

Deferred Tax Assets In Process Research And Development

DeferredTaxAssetsInProcessResearchAndDevelopment

31220000

CY2022Q4

us-gaap

Deferred Tax Assets In Process Research And Development

DeferredTaxAssetsInProcessResearchAndDevelopment

20835000

CY2023Q4

verv

Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs

DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts

64255000

CY2022Q4

verv

Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs

DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts

28650000

CY2023Q4

us-gaap

Deferred Tax Assets Deferred Income

DeferredTaxAssetsDeferredIncome

5525000

CY2022Q4

us-gaap

Deferred Tax Assets Deferred Income

DeferredTaxAssetsDeferredIncome

77000

CY2023Q4

verv

Deferred Tax Assets Stock Based Compensation

DeferredTaxAssetsStockBasedCompensation

8926000

CY2022Q4

verv

Deferred Tax Assets Stock Based Compensation

DeferredTaxAssetsStockBasedCompensation

3669000

CY2023Q4

us-gaap

Deferred Tax Assets Other

DeferredTaxAssetsOther

134000

CY2022Q4

us-gaap

Deferred Tax Assets Other

DeferredTaxAssetsOther

97000

CY2023Q4

us-gaap

Deferred Tax Assets Regulatory Assets And Liabilities

DeferredTaxAssetsRegulatoryAssetsAndLiabilities

20646000

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent

EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent

0.003

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent

EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent

0.009

CY2023

verv

Effective Income Tax Rate Reconciliation Executive Compensation Percent

EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent

-0.002

CY2022

verv

Effective Income Tax Rate Reconciliation Executive Compensation Percent

EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent

-0.008

CY2021

verv

Effective Income Tax Rate Reconciliation Executive Compensation Percent

EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent

-0.011

CY2023

verv

Effective Income Tax Rate Reconciliation Permanent Items

EffectiveIncomeTaxRateReconciliationPermanentItems

-0.001

CY2022

verv

Effective Income Tax Rate Reconciliation Permanent Items

EffectiveIncomeTaxRateReconciliationPermanentItems

-0.002

CY2021

verv

Effective Income Tax Rate Reconciliation Permanent Items

EffectiveIncomeTaxRateReconciliationPermanentItems

-0.001

CY2023

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.082

CY2022

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.084

CY2021

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.061

CY2023

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment

0.036

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment

0.056

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment

0.045

CY2023

verv

Effective Income Tax Rate Reconciliation Other

EffectiveIncomeTaxRateReconciliationOther

-0.003

CY2022

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0

CY2021

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0

CY2023Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

51295000

CY2022Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

43779000

CY2023Q4

verv

Deferred Tax Assets Capitalized Costs Net Of Amortization

DeferredTaxAssetsCapitalizedCostsNetOfAmortization

10844000

CY2022Q4

verv

Deferred Tax Assets Capitalized Costs Net Of Amortization

DeferredTaxAssetsCapitalizedCostsNetOfAmortization

11095000

CY2023Q4

us-gaap

Deferred Tax Assets In Process Research And Development

DeferredTaxAssetsInProcessResearchAndDevelopment

31220000

CY2022Q4

us-gaap

Deferred Tax Assets In Process Research And Development

DeferredTaxAssetsInProcessResearchAndDevelopment

20835000

CY2023Q4

verv

Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs

DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts

64255000

CY2022Q4

verv

Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs

DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts

28650000

CY2023Q4

us-gaap

Deferred Tax Assets Deferred Income

DeferredTaxAssetsDeferredIncome

5525000

CY2022Q4

us-gaap

Deferred Tax Assets Deferred Income

DeferredTaxAssetsDeferredIncome

77000

CY2023Q4

verv

Deferred Tax Assets Stock Based Compensation

DeferredTaxAssetsStockBasedCompensation

8926000

CY2022Q4

verv

Deferred Tax Assets Stock Based Compensation

DeferredTaxAssetsStockBasedCompensation

3669000

CY2023Q4

us-gaap

Deferred Tax Assets Other

DeferredTaxAssetsOther

134000

CY2022Q4

us-gaap

Deferred Tax Assets Other

DeferredTaxAssetsOther

97000

CY2023Q4

us-gaap

Deferred Tax Assets Regulatory Assets And Liabilities

DeferredTaxAssetsRegulatoryAssetsAndLiabilities

20646000

CY2022Q4

us-gaap

Deferred Tax Assets Regulatory Assets And Liabilities

DeferredTaxAssetsRegulatoryAssetsAndLiabilities

22285000

CY2023Q4

verv

Deferred Tax Asset Accrued Expenses

DeferredTaxAssetAccruedExpenses

3726000

CY2022Q4

verv

Deferred Tax Asset Accrued Expenses

DeferredTaxAssetAccruedExpenses

5024000

CY2023Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

196571000

CY2022Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

135511000

CY2023Q4

us-gaap

Deferred Tax Liabilities Property Plant And Equipment

DeferredTaxLiabilitiesPropertyPlantAndEquipment

1207000

CY2022Q4

us-gaap

Deferred Tax Liabilities Property Plant And Equipment

DeferredTaxLiabilitiesPropertyPlantAndEquipment

881000

CY2023Q4

verv

Deferred Tax Liabilities Right Of Use Asset

DeferredTaxLiabilitiesRightOfUseAsset

-23254000

CY2022Q4

verv

Deferred Tax Liabilities Right Of Use Asset

DeferredTaxLiabilitiesRightOfUseAsset

-24994000

CY2023Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

24461000

CY2022Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

25875000

CY2023Q4

us-gaap

Deferred Tax Assets Liabilities Net

DeferredTaxAssetsLiabilitiesNet

172110000

CY2022Q4

us-gaap

Deferred Tax Assets Liabilities Net

DeferredTaxAssetsLiabilitiesNet

109636000

CY2022Q4

us-gaap

Deferred Tax Assets Regulatory Assets And Liabilities

DeferredTaxAssetsRegulatoryAssetsAndLiabilities

22285000

CY2023Q4

verv

Deferred Tax Asset Accrued Expenses

DeferredTaxAssetAccruedExpenses

3726000

CY2022Q4

verv

Deferred Tax Asset Accrued Expenses

DeferredTaxAssetAccruedExpenses

5024000

CY2023Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

196571000

CY2022Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

135511000

CY2023Q4

us-gaap

Deferred Tax Liabilities Property Plant And Equipment

DeferredTaxLiabilitiesPropertyPlantAndEquipment

1207000

CY2022Q4

us-gaap

Deferred Tax Liabilities Property Plant And Equipment

DeferredTaxLiabilitiesPropertyPlantAndEquipment

881000

CY2023Q4

verv

Deferred Tax Liabilities Right Of Use Asset

DeferredTaxLiabilitiesRightOfUseAsset

-23254000

CY2022Q4

verv

Deferred Tax Liabilities Right Of Use Asset

DeferredTaxLiabilitiesRightOfUseAsset

-24994000

CY2023Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

24461000

CY2022Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

25875000

CY2023Q4

us-gaap

Deferred Tax Assets Liabilities Net

DeferredTaxAssetsLiabilitiesNet

172110000

CY2022Q4

us-gaap

Deferred Tax Assets Liabilities Net

DeferredTaxAssetsLiabilitiesNet

109636000

CY2023Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

172110000

CY2022Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

109636000

CY2023Q4

us-gaap

Deferred Tax Assets Net

DeferredTaxAssetsNet

0

CY2022Q4

us-gaap

Deferred Tax Assets Net

DeferredTaxAssetsNet

0

CY2023

us-gaap

Valuation Allowance Deferred Tax Asset Change In Amount

ValuationAllowanceDeferredTaxAssetChangeInAmount

62500000

CY2023

verv

Change In Ownership Description

ChangeInOwnershipDescription

An ownership change occurs when the ownership percentages of 5% or greater shareholders change by more than 50% over a three-year period.

CY2023Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

0

CY2022Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

0

CY2023

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

0

CY2022

verv

Lease Rent Payment

LeaseRentPayment

1800000

CY2023

us-gaap

Defined Contribution Plan Maximum Annual Contributions Per Employee Amount

DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount

7500

CY2023Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

172110000

CY2022Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

109636000

CY2023Q4

us-gaap

Deferred Tax Assets Net

DeferredTaxAssetsNet

0

CY2022Q4

us-gaap

Deferred Tax Assets Net

DeferredTaxAssetsNet

0

CY2023

us-gaap

Valuation Allowance Deferred Tax Asset Change In Amount

ValuationAllowanceDeferredTaxAssetChangeInAmount

62500000

CY2023

verv

Change In Ownership Description

ChangeInOwnershipDescription

An ownership change occurs when the ownership percentages of 5% or greater shareholders change by more than 50% over a three-year period.

CY2023Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

0

CY2022Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

0

CY2023

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

0

CY2022

verv

Lease Rent Payment

LeaseRentPayment

1800000

CY2023

us-gaap

Defined Contribution Plan Maximum Annual Contributions Per Employee Amount

DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount

7500

Name	View Source	Status
0000950170-24-020633-index-headers.html	Edgar Link	pending
0000950170-24-020633-index.html	Edgar Link	pending
0000950170-24-020633.txt	Edgar Link	pending
0000950170-24-020633-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img244475160_0.jpg	Edgar Link	pending
img244475160_1.jpg	Edgar Link	pending
img244475160_2.jpg	Edgar Link	pending
img244475160_3.jpg	Edgar Link	pending
img244475160_4.jpg	Edgar Link	pending
img244475160_5.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
verv-20231231.htm	Edgar Link	pending
verv-20231231.xsd	Edgar Link	pending
verv-ex10_10.htm	Edgar Link	pending
verv-ex10_17.htm	Edgar Link	pending
verv-ex10_24.htm	Edgar Link	pending
verv-ex10_29.htm	Edgar Link	pending
verv-ex10_7.htm	Edgar Link	pending
verv-ex10_8.htm	Edgar Link	pending
verv-ex10_9.htm	Edgar Link	pending
verv-ex23_1.htm	Edgar Link	pending
verv-ex31_1.htm	Edgar Link	pending
verv-ex31_2.htm	Edgar Link	pending
verv-ex32_1.htm	Edgar Link	pending
verv-ex32_2.htm	Edgar Link	pending
verv-ex97.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
verv-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VERV
Verve Therapeutics, Inc. Stock $verv

2023 Q4 Form 10-K Financial Statement

#000095017024020633 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VERV Verve Therapeutics, Inc. Stock $verv

2023 Q4 Form 10-K Financial Statement

#000095017024020633 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VERV
Verve Therapeutics, Inc. Stock $verv